Hugh O'Dowd
Chairman presso ONK Therapeutics Ltd.
Patrimonio netto: 278 615 $ in data 31/03/2024
Profilo
Hugh O'Dowd currently works at ONK Therapeutics Ltd., as Independent Non-Executive Chairman from 2021.
Mr. O'Dowd also formerly worked at TherapeuticsMD, Inc., as President, Chief Executive Officer & Director from 2021 to 2022, BioNTech US, Inc., as President, Chief Executive Officer & Director from 2016 to 2020, Spexis Ltd., as Director, Puma Biotechnology, Inc., as Independent Director from 2019 to 2021, Novartis Oncology, Inc., as Chief Commercial Officer & Head-Global Strategy from 2011 to 2015, Novartis UK Ltd., as President & General Manager from 2015 to 2016, Novartis Ireland Ltd., as President & General Manager from 2015 to 2016, and Novartis International Pharmaceutical Ltd., as General Manager from 2015 to 2016.
Mr. O'Dowd received his undergraduate degree from Loyola University of Chicago and Masters Business Admin degree from Kellstadt Graduate School of Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
THERAPEUTICSMD, INC.
1.15% | 20/04/2023 | 121 666 ( 1.15% ) | 278 615 $ | 31/03/2024 |
Posizioni attive di Hugh O'Dowd
| Società | Posizione | Inizio |
|---|---|---|
ONK Therapeutics Ltd.
 ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | Chairman | 14/01/2021 |
Precedenti posizioni note di Hugh O'Dowd
| Società | Posizione | Fine |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Director/Board Member | 15/06/2021 |
| NEON THERAPEUTICS, INC. | Chief Executive Officer | 06/05/2020 |
Novartis UK Ltd.
 Novartis UK Ltd. Pharmaceuticals: MajorHealth Technology Novartis UK Ltd. is an international pharmaceutical company. It strives to discover ways to improve and extend people’s lives. The company is headquartered in Frimley, the United Kingdom. | President | 01/01/2016 |
Novartis International Pharmaceutical Ltd.
 Novartis International Pharmaceutical Ltd. Pharmaceuticals: MajorHealth Technology Novartis International Pharmaceutical Ltd. manufactures and distributes pharmaceutical products. The company is headquartered in Ireland. | Corporate Officer/Principal | 01/01/2016 |
| Novartis Ireland Ltd. | President | 01/01/2016 |
Formazione di Hugh O'Dowd
| Loyola University of Chicago | Undergraduate Degree |
| Kellstadt Graduate School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| SPEXIS AG | Health Technology |
| THERAPEUTICSMD, INC. | Health Technology |
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| Aziende private | 6 |
|---|---|
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Health Technology |
Novartis UK Ltd.
Novartis UK Ltd. Pharmaceuticals: MajorHealth Technology Novartis UK Ltd. is an international pharmaceutical company. It strives to discover ways to improve and extend people’s lives. The company is headquartered in Frimley, the United Kingdom. | Health Technology |
| Novartis Ireland Ltd. | |
Novartis International Pharmaceutical Ltd.
Novartis International Pharmaceutical Ltd. Pharmaceuticals: MajorHealth Technology Novartis International Pharmaceutical Ltd. manufactures and distributes pharmaceutical products. The company is headquartered in Ireland. | Health Technology |
BioNTech US, Inc.
 BioNTech US, Inc. BiotechnologyHealth Technology BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA. | Health Technology |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | Health Technology |
- Borsa valori
- Insiders
- Hugh O'Dowd
